Dependence, Tolerance, and Addiction to Benzodiazepines: Clinical and Pharmacokinetic Considerations*

DAVID J. GREENBLATT and RICHARD I. SHADER
Clinical Pharmacology Unit
Massachusetts General Hospital
Boston, Massachusetts 02114;
Psychopharmacology Research Laboratory
Massachusetts Mental Health Center
Boston, Massachusetts 02115

I. INTRODUCTION ........................................ 14
II. SORTING OUT TERMINOLOGY .......................... 14
III. ADDICTION ............................................ 15

*Presented at Symposium on Drug Disposition in Man held in Sarasota, Florida, November 6-11, 1977 under the auspices of the American Society for Pharmacology and Experimental Therapeutics.
I. INTRODUCTION

Benzodiazepine derivatives are among the most widely used pharmacologic agents in the Western world. Some 10 to 20% of ambulatory adults in the United States and other Western nations ingest benzodiazepine derivatives on a regular basis due to anxiety, tension, or insomnia [1, 2]. Given the widespread extent of benzodiazepine use for therapeutic purposes, the issue of benzodiazepine misuse is of considerable medical and social importance. Unfortunately, achievement of a rational clinical perspective of this problem has been made nearly impossible by a barrage of irresponsible and sensationalistic journalism by popular newspapers, periodicals, and television. This review considers clinical and pharmacokinetic evidence relating to tolerance, habituation, and addiction to benzodiazepine derivatives. Emphasis is placed upon the clinical implications of research findings.

II. SORTING OUT TERMINOLOGY

The terms tolerance, addiction, habituation, and dependence are subject to much misunderstanding. Furthermore, they carry unfortunate connotations that associate them with "hard-core" drug addiction. Reasonably precise definitions for these terms must be developed prior to discussion of any specific clinical problem [3-5]. Our definitions are only operational, developed to facilitate and clarify understanding of the problems discussed within this particular article.

Addiction is used synonymously with physiologic dependence, and denotes a syndrome of physiologic drug dependence. Addiction generally follows prolonged drug exposure, although the length of time necessary to develop addiction varies greatly among classes of drugs. True addiction is not present unless drug discontinuation is
followed by an objective withdrawal syndrome, characterized by objective physiologic changes. Habituation, or psychological dependence, may coexist with true addiction, but this is not necessarily the case. The habituated individual craves or desires drug exposure, and experiences unpleasant subjective sensations when deprived of the drug. However, objective withdrawal syndromes do not occur unless habituation coexists with addiction. Again, habituation is generally associated with long-term drug exposure. Tolerance is of two major types, either or both of which may coexist with habituation or addiction. Receptor-site tolerance really means adaptation, and refers to the effect that duration of exposure of the central nervous system (CNS) receptor site to any given drug concentration may have upon the clinical and physiologic manifestations of the drug-receptor interaction. That is, a given CNS receptor-site drug concentration may have a different effect depending on how long and in what concentration the receptor has been exposed to the drug. This type of tolerance usually tends to reduce clinical drug effects as the duration of drug exposure proceeds. A common example involves the acute intoxicant effects of ethyl alcohol. The alcohol concentration in the blood (and presumably also at the receptor site in the brain) following acute ingestion of ethanol may be higher during recovery from acute intoxication than earlier when subjective manifestations of intoxication are maximal. Pharmacokinetic or metabolic tolerance, on the other hand, denotes the effect of prolonged drug exposure upon its own pharmacokinetic properties. The term usually describes the phenomenon of increased drug clearance associated with repeated ingestion, as in the case of prolonged barbiturate exposure. The clinical consequence of this is that steady-state blood concentrations of a drug administered on a chronic basis will progressively fall despite continued administration of the same dose.

The following sections review the relation of these definitions to published clinical studies on benzodiazepine derivatives.

III. ADDICTION

Reliable reports of true addiction to benzodiazepine derivatives do exist. The first such report was published by Hollister and associates [6] in 1961. They administered chlordiazepoxide, 100 to 600 mg daily, to 36 hospitalized psychiatric patients for periods of 1 to 7 months. Eleven patients were abruptly changed to placebo on a single-blind basis. Ten of the 11 developed objective or subjective signs of withdrawal,
including depression in six, worsening of psychosis in five, insomnia and agitation in five, decreased appetite in four, seizures in three, and twitching in one. Most symptoms appeared 4 to 8 days after drug discontinuation, and had largely subsided by the tenth day. Between 1963 and 1972, additional nine case reports were published [7-15] (Table 1). Several further reports have appeared since this time [16-22], including descriptions of apparent withdrawal syndromes in neonates following maternal exposure to benzodiazepines [23, 24]. The characteristics of subsequent reports generally are similar to the description by Hollister and associates [6]. The majority of patients had been ingesting very large doses of the drugs for extended periods of time. Signs and symptoms of withdrawal resembled those associated with discontinuation of any sedative-hypnotic agent to which addiction has developed, and ranged from agitation, tachycardia, and diaphoresis to more serious consequences such as hallucinations, psychosis, and seizures. With the exception of oxazepam, benzodiazepine derivatives clinically available in the United States through 1976 are characterized by a long duration of action and/or the presence of pharmacologically-active metabolites [25, 26]. This probably explains why symptoms of withdrawal generally do not appear until several days after drug discontinuation.

Although these case reports constitute valid observations, they provide little or no perspective on the incidence or extent of benzodiazepine addiction. Unfortunately, case reports such as these often are taken out of context and portrayed as everyday occurrences by the popular media. Considering the extent of use of diazepam and other benzodiazepines, true addiction is probably exceedingly unusual, and when it occurs is probably confined to those individuals with "addiction-prone" personalities who ingest very large doses [27]. There are few systematic studies of problems associated with benzodiazepine withdrawal following ingestion of therapeutic doses. Covi and associates [28, 29] investigated the effect of abrupt discontinuation of chlordiazepoxide (45 mg/day) after long-term treatment. Their findings suggested that a mild abstinence syndrome, consisting mainly of subjective feelings of anxiety and tension as well as minor symptoms (such as trembling, poor appetite, and faintness or dizziness) may be a consequence of chlordiazepoxide withdrawal in some individuals who had taken the drug continuously for 20 weeks. It should be emphasized that such manifestations can be very difficult to distinguish from recrudescence of the original anxiety-related symptoms for which the drug was initially prescribed.

On the basis of currently available evidence, it seems that widespread concern about benzodiazepine addiction is based largely upon irresponsible journalism rather than sound scientific evidence [27, 30].
IV. HABITUATION

There is little reliable data on the nature and extent of habituation or psychological dependence associated with benzodiazepine treatment. Many individuals ingest these drugs over long periods of time, but this certainly does not imply true habituation nor that their use of these derivatives is inappropriate, excessive, or dangerous. In the vast majority of cases it is likely that long-term benzodiazepine use reflects the continued presence of symptomatic anxiety or insomnia, which would recur and lead to considerable emotional discomfort were the drugs discontinued. Winstead and associates [31] studied the "habituating" potential of diazepam in a series of hospitalized psychiatric patients who were allowed "free access" to diazepam. Patients could receive diazepam on request in doses of up to 10 mg every 4 hr. The availability of diazepam did not lead to excessive drug-seeking behavior nor was there evidence of development of dependence. The 83 patients studied over a 6-month period requested diazepam on the average of once every 3 days, and 27% of patients never requested the drug. Hubbard and Kripke [32] studied the extent of flurazepam use among discharged psychiatric patients. Outpatient flurazepam use was no more common among those who had received the drug while hospitalized than in those who did not, suggesting that in-hospital flurazepam prescribing did not lead to dependence.

Data on benzodiazepine habituation by drug abusers is largely anecdotal. We are commonly told that diazepam is a "street drug" and that it ranks high among drugs of abuse [22, 33, 34]. However, reliable documentation of this is lacking. Estimates of the incidence of benzodiazepine abuse must always be considered in the context of its extensive use for therapeutic purposes and the easy availability of the compound.

It may be very difficult to distinguish psychological dependence from true physiologic addiction. Adam and associates [35] studied the effect of nightly ingestion of nitrazepam (5 mg) for 10 weeks upon sleep patterns and subjective responses of 10 volunteers aged 41 to 62 years. The mean total sleep duration during the nitrazepam treatment period increased significantly over the pretreatment control period. However, after nitrazepam withdrawal the average total sleep duration was less than that during the prenitrazepam baseline condition. The findings suggest that withdrawal of nitrazepam following prolonged use leads to impairment of total sleep duration. However, the subjective nature of the withdrawal experience was not discussed. The findings do not establish whether prolonged nitrazepam use leads to physiologic dependence (addiction), psychological dependence (habituation), or both. It is evident that considerable uncertainty exists in this area,
### TABLE 1

Case Reports of Addiction to Benzodiazepines

<table>
<thead>
<tr>
<th>Refs.</th>
<th>Patient characteristics (age, sex)</th>
<th>Drug</th>
<th>Dose (mg/day)</th>
<th>Duration</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>52, female</td>
<td>Diazepam</td>
<td>40–60</td>
<td>3 months</td>
<td>Acute delirium tremens-like syndrome upon discontinuation of drug</td>
</tr>
<tr>
<td>8</td>
<td>39, female; history of barbiturate and alcohol abuse</td>
<td>Diazepam</td>
<td>Maximum of 500</td>
<td>Weeks</td>
<td>Diazepam withdrawal syndrome suppressed by ethanol</td>
</tr>
<tr>
<td>9</td>
<td>51, male</td>
<td>Nitrazepam</td>
<td>20 mg nightly</td>
<td>Years</td>
<td>Acute delirium tremens-like syndrome upon discontinuation of drug</td>
</tr>
<tr>
<td>10</td>
<td>23, female</td>
<td>Diazepam</td>
<td>60</td>
<td>1 year</td>
<td>Tremulous, diaphoretic, and agitated upon discontinuation of drug</td>
</tr>
<tr>
<td>11</td>
<td>44, female</td>
<td>Chlordiazepoxide</td>
<td>160</td>
<td>Dosage increased over 2 months</td>
<td>Withdrawal syndrome prevented by trifluoperazine</td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>Gender</td>
<td>Drug</td>
<td>Dosage</td>
<td>Duration</td>
</tr>
<tr>
<td>---</td>
<td>-----</td>
<td>--------</td>
<td>-------------</td>
<td>--------</td>
<td>-----------</td>
</tr>
<tr>
<td>12</td>
<td>29, male</td>
<td>Oxazepam</td>
<td>90</td>
<td>18 months</td>
<td>Severe agitation and depression upon discontinuation of drug</td>
</tr>
<tr>
<td>13</td>
<td>20, male, with Diazepam</td>
<td>40–60</td>
<td>11 days</td>
<td>Severe withdrawal syndrome and death 3 days after drug discontinuation</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>29, female</td>
<td>Oxazepam</td>
<td>400–600</td>
<td>6 weeks</td>
<td>Acute toxic delirium 5 days after discontinuation of drug</td>
</tr>
<tr>
<td>15</td>
<td>37, female</td>
<td>Chlordiazepoxide</td>
<td>50–140</td>
<td>Years</td>
<td>Abdominal pains, diaphoresis, hallucinations upon discontinuation; symptoms suppressed by reinstituting drug</td>
</tr>
</tbody>
</table>
We recommend that physicians discuss these issues with all patients who are initiating benzodiazepine therapy. They are best told that treatment is likely to cause some symptomatic relief of their emotional disturbances, and that discontinuation of treatment may be followed by reappearance of symptoms. It is our practice to reassure patients that true addiction is unlikely, and that the hazards of benzodiazepines as depicted by the popular media are greatly exaggerated.

V. RECEPTOR-SITE TOLERANCE

Although habituation and addiction to benzodiazepines appears to be very uncommon, some degree of receptor-site tolerance or adaptation probably occurs in every individual exposed to the drug. Considerable circumstantial and clinical evidence supports this impression. We have observed that subjective perceptions of feeling "spaced out" or reduction in the speed and clarity of thought processes following single 25-mg oral doses of chloridazepoxide depend more upon the rate at which blood levels are achieved following the dose than upon the blood level measured at the time that the subjective effect is assessed [36]. MacLeod and associates [37] have found that the extent of psychomotor impairment attributable to a single oral dose of diazepam is far greater on the "upswing" of the curve than on the "downswing" of the curve, even though plasma levels at the time of testing may be similar. These findings support the clinical importance of drug absorption rate or the rate of change of drug levels as important determinants of subjective and objective clinical effects. Similar findings are reported by Blicing [38] in a comparison of diazepam and oxazepam.

Clinical observations on the time course of subjective sedative effects following single and multiple doses of benzodiazepines further support the concept of adaptation. Individuals initiating diazepam therapy often feel subjective drowsiness during the first day or two of treatment. If the same dose is continued, the sensation of drowsiness may abate [39] even though there is extensive drug accumulation [39-42]. Blood concentrations of diazepam and desmethyldiazepam at the time that drowsiness has essentially disappeared may greatly exceed those measured during the early part of therapy when drowsiness was symptomatically evident. The findings are similar with single- and multiple-dose flurazepam therapy. After a single oral dose of flurazepam, little or no unchanged flurazepam is measured in the bloodstream. However, there is a gradual increase in levels of desalkylflurazepam, a pharmacologically active metabolite,
FIG. 1. A healthy male volunteer ingested 30 mg of flurazepam hydrochloride (Dalmane), following which multiple venous blood samples were drawn over the next 4 days. Plasma samples were analyzed by electron-capture gas-liquid chromatography after extraction with benzene. Intact flurazepam and/or its hydroxyethyl metabolite were detected only in samples drawn during the first 2 hr, and in concentrations so low as to be barely measurable. However, relatively high concentrations of the major pharmacologically active metabolite, desalkylflurazepam, appeared in plasma. Peak levels were reached 24 hr after the flurazepam dose, and thereafter declined with an apparent half-life of 47.5 hr.

which probably accounts for its clinical effects (Fig. 1). Peak levels of desalkylflurazepam may not be reached until 24 hr after the dose, at which time patients generally perceive little or no drug effects. Repeated ingestion of flurazepam leads to continued accumulation of this metabolite [43], despite a lack of any sensation of cumulative drowsiness or sedation [44, 45]. Thus the sleep-inducing effect of
any given dose of flurazepam may be related more to the rate at which
the metabolite is generated than to the absolute blood level.

Most of these observations relate to unwanted effects of benzodi-
azepines—drowsiness, psychomotor impairment, or excessive seda-
tion. It appears that tolerance to the therapeutic effects of the drug
develop much less readily, and that the sedative and antianxiety drug
effects become dissociated with multiple-dose therapy. Thus repeated
ingestion of diazepam may lead to excessive sedation early in the course
of therapy. As treatment is continued at the same dose, the subjective
sensation of drowsiness or oversedation abates, while the antianxiety
effects remain present or even become accentuated. Unfortunately,
reliable clinical documentation of the time course of these two effects
is largely lacking, but the observation is well documented in animal
studies [46-49].

The phenomenon of receptor-site tolerance or adaptation to benzo-
diazepines greatly complicates interpretation of blood levels and phar-
camokinetics in relation to clinical effect. A given blood level may
have one clinical effect at one time but a different effect at a later
time after a period of drug exposure has elapsed. Furthermore, it
is conceivable that blood concentrations and pharmacokinetic proper-
ties bear one type of relationship to nonspecific sedative effects but
an entirely different relationship to clinical antianxiety effects.

VI. METABOLIC TOLERANCE

Objective pharmacokinetic and metabolic effects of long-term ben-
zodiazepine administration are more easily studied than effects of re-
peated administration upon mood, effect, and psychomotor function.
Animal investigations indicate that administration of large doses of
benzodiazepine derivatives under certain conditions can produce en-
zyme induction [50]. Clinical studies, however, indicate that en-
zyme induction by benzodiazepines, if it occurs, is seldom of clinical
significance. Several workers have found no effect of benzodiazepine
derivatives upon the pharmacokinetics of phenylbutazone, antipyrine,
or ethanol [50]. Vesell and associates [51] found that 7 days of
prazepam administration (30 mg/day) to healthy males did not stimu-
late the metabolism of either prazepam itself or of antipyrine. Nu-
merous studies indicate that benzodiazepines, unlike barbiturates, do
not stimulate the metabolism of oral anticoagulants [50].

The effect of benzodiazepine treatment upon their own metabolism
is controversial. Klotz and associates [52] found that the elimination
half-life of diazepam following multiple doses is prolonged in comparison with that observed following a single dose, possibly due to the inhibitory effect of the metabolite, desmethyldiazepam, upon diazepam clearance. On the other hand, the findings of Kanto et al. [53] and Sellman et al. [54] suggest that multiple-dose therapy with diazepam in humans causes induction of diazepam biotransformation. Epidemiologic studies indicate that unwanted drowsiness due to diazepam and chlordiazepoxide is more common in nonsmokers than in smokers [55], possibly because cigarette smoking stimulates the biotransformation and clearance of benzodiazepine derivatives. However, the pharmacokinetic studies of Klotz and associates [56] found no effect of smoking on diazepam clearance.

VII. COMMENT

The hazards of benzodiazepine addiction and habituation probably have been greatly exaggerated. Some individuals receiving benzodiazepines for the symptomatic treatment of anxiety or insomnia over long periods of time may experience dysphoric symptoms when the drugs are discontinued. This probably does not represent addiction or dependence, but rather reappearance of the disease for which treatment was originally initiated. Some degree of tolerance to the non-specific sedative effects of benzodiazepines probably develops in virtually all individuals who receive the drugs. This is not necessarily unfavorable, since it is not clear whether tolerance also develops to the therapeutic effects. Clinically important enzyme induction attributable to benzodiazepines appears to occur seldom, if ever. This accounts for why so few pharmacokinetic drug interactions have been reportedly associated with benzodiazepine treatment.

Acknowledgments

We are grateful for the collaboration and assistance of Jerold S. Harmatz, Ann Werner, Kate Franke, Marcia D. Allen, and Dr. Dean S. MacLaughlin. Dr. MacLaughlin is supported by Grant GM–23430 from the United States Public Health Service to the Boston Collaborative Drug Surveillance Program.

Supported in part by Grant MH–12279 from the United States Public Health Service.
REFERENCES

[1] D. J. Greenblatt, R. I. Shader, and J. Koch-Weser, "Psycho-
tropic Drug Use in the Boston Area: A Report from the Boston

National Study of the Extent of Antianxiety/Sedative Drug

[3] H. Isbell, "Clinical Aspects of the Various Forms of Nonmed-
cal Use of Drugs," Anesth. Analg. (Cleveland), 50, 886-905
(1971).

and Dependence on, Some Nonopiate Psychotropic Drugs,"


"Withdrawal Reactions from Chlordiazepoxide (Librium),"
Psychopharmacologia, 2, 63-68 (1961).

[7] H. H. Barten, "Toxic Psychosis with Transient Dysmne-
tic Syndrome Following Withdrawal from Valium," Am. J.
Psychiatry, 121, 1210-1211 (1965).

[8] A. W. Clare, "Diazepam, Alcohol, and Barbiturate Abuse,"

[9] L. Darcy, "Delirium Tremens Following Withdrawal of Ni-

1, 112 (1967).


[15] J. Slater, "Suspected Dependence on Chlordiazepoxide Hydro-

[16] K. Frueingsgaard, "Withdrawal Psychosis: A Study of 30 Con-


A. Bliding, "Effects of Different Rates of Absorption of Two Benzodiazepins on Subjective and Objective Parameters," Ibid., 7, 201-211 (1974).


[47] L. Stein and B. D. Berger, "Psychopharmacology of 7-Chloro-5-(o-chlorophenyl)-1, 3-dihydro-3-hydroxy-2H-1, 4-benzo


[49] K. Matsuki and T. Iwamoto, "Development of Tolerance to Tran-


